THNRAmplify Weight Loss Drug & Treatment ETF
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
Amplify ETFs · Since 2024 (1 year)
0.59%
#2801 out of 5,332 ETFs
$4M
#4903 out of 5,332 ETFs
1.69%
1 year
#3672 out of 5,332 ETFs
Performance
1 Year
+13.6%
3 Years
N/A
5 Years
N/A
What's inside
Asset allocation
Sector breakdown
Top holdings
Risk profile
19.7%
Moderate
-32.5%
Worst peak-to-trough loss
N/A
N/A
Similar ETFs
Our take
Structural notes on how this fund behaves. Read our guide on the 6 warning signs.
Thematic ETF — launched after the rally
Thematic funds are typically launched after a theme has delivered its strong returns. Morningstar's 2024 Global Thematic Funds Landscape finds that only about 1 in 10 thematic funds have survived and beaten a broad global equity benchmark over the past 15 years — roughly 60% have been closed outright. The narrative is always compelling; the track record rarely is.
Source: Morningstar, 'Global Thematic Funds Landscape' (2024)
Why we flagged this: Narrow thematic name, launched in the last 3 years, $4M in assets (under our $500M threshold).
Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More
Data updated on 2026-05-05